Yuekang Pharmaceutical: Subsidiary injection YKYY031 obtained approval for clinical trials from the National Medical Products Administration.

Yuankang Pharmaceutical announced that its wholly-owned subsidiaries Beijing Yuankang Innovation Medicine Technology Co., Ltd. and Hangzhou Tianlong Pharmaceutical Co., Ltd. recently obtained the approval and issuance of the "Drug Clinical Trial Approval Letter" from the National Medical Products Administration to conduct late-stage clinical trials of injectable YKYY031 for the treatment of advanced solid tumors. Injectable YKYY031 is a universal mRNA tumor vaccine intended for the treatment of advanced solid tumors.